Home › NCT07473128

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
* Complete recovery from prior anti-tumor surgical procedures
* Measurable and evaluable disease through tumor assessment
* Willingness to participate and sign informed consent form

Exclusion Criteria:

* Extensive Stage Small Cell Lung Cancer
* Active cardiovascular disease
* Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
* Pregnant or nursing women

About the study

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:

Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?

Participants will be randomised to receive either trilaciclib or placebo.

What is being tested

• Trilaciclib (drug)
• Saline (0.9% NaCl) (drug)

Sponsor: Pharmacosmos A/S · Participants: 120 · Started: Jun 30, 2026

Contact the study team

• Pharmacosmos A/S Clinical and non-clinical research · Phone: +4559485959

Official record on ClinicalTrials.gov — NCT07473128

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.